Exo Therapeutics is a small molecule drug discovery company addressing intractable pharmaceutical targets. Most small molecules are designed to bind the active site of an enzyme; however, many active sites are inaccessible or are similar to non-target enzymes. Exo Therapeutics is targeting exosites, which are distal substrate-enzyme sites that occur widely across the proteome. Exo uses their ExoSight platform to develop a pipeline of potent drug candidates that reprogram enzyme activity for oncology, inflammation and other diseases.
Exo aims to expand the druggable universe with exosites that represent ~30% of known target space. Through the use of CryoEM structures, structural biology and protein engineering, Exo has built proprietary capabilities for systematized ligand discovery.